IHC News and Research

RSS

Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer

Polaris Group announced today that data from preclinical studies suggest ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, may be effective in treating acute myeloid leukemia (AML), glioblastoma multiforme (GBM) and bladder cancer.

8 Apr 2011

VisualSonics demonstrates Vevo LAZR imaging system at AACR conference

VisualSonics Inc., a leader in real time, in vivo, high-resolution micro-imaging systems and a wholly-owned subsidiary of SonoSite Inc., is demonstrating the recently announced Vevo LAZR Photoacoustics Imaging system at the American Association of Cancer Research's annual conference.

5 Apr 2011

Routine periodic fasting can reduce risk of coronary heart disease

Fasting has long been associated with religious rituals, diets, and political protests. Now new evidence from cardiac researchers at the Intermountain Medical Center Heart Institute demonstrates that routine periodic fasting is also good for your health, and your heart.

4 Apr 2011

USPTO grants patent to HistoRx methods for digital microscopy standardization

HistoRx, Inc., announced today that the U.S. Patent and Trademark Office has granted a patent protecting the company's methods for standardization of digital microscopy instruments in order to go beyond imaging to generating high-quality reproducible data that precisely relates to biomarker concentrations in tissue sections.

22 Mar 2011

CALP, HistoRx collaborate to co-develop new generation of tissue-based imaging solutions

Caliper Life Sciences, Inc. and HistoRx, Inc., today announced a collaboration to co-develop a new generation of tissue-based imaging and analysis solutions, based on immuno-fluorescence, that will deliver accurate, quantitative, and reproducible measurements of proteins in tissue samples.

11 Mar 2011

New rapid and inexpensive test can effectively identify never-smoking group with lung adenocarcinoma

An inexpensive and rapid testing method can effectively identify a sub-group of never-smoking lung cancer patients whose tumors express a molecule associated with increased risk of disease progression or recurrence, US researchers have found.

25 Feb 2011

Biocare, HJF sign license agreement to distribute antibody against prostate cancer

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has signed a licensing agreement with Biocare Medical, a biotechnology company based in Concord, Calif., for the exclusive worldwide sales and distribution rights for the immunohistochemistry of an antibody designed to detect tumor prevalence in prostate cancer patients.

18 Feb 2011

Numira acquires Ricerca' Efficacy Pharmacology operating unit

Numira Biosciences, a specialty contract research organization and leader in high resolution, 3D imaging services and visualization software for the life science market, announced today that it has acquired the Efficacy Pharmacology operating unit of Ricerca Biosciences, LLC., located in Bothell, WA.

14 Feb 2011

TD2 and Flagship Biosciences offer combined oncology and pathology services

TGen Drug Development (TD2) and Flagship Biosciences today announced a strategic alliance that should help speed new drugs safely into human testing and quickly benefit cancer patients.

27 Jan 2011

Study results presented at ASCO-GI reinforce value of Genomic Health's Oncotype DX Colon Cancer test

Genomic Health, Inc. today announced presentation of three studies at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium, including one finding that high tumor grade was not a marker of higher recurrence risk in stage II colon cancer, suggesting that other markers, such as the Oncotype DX® Recurrence Score® (RS) test as well as T-stage and mismatch repair (MMR) status, should be considered by physicians during the treatment decision-making process.

25 Jan 2011

Study results of Pathwork Diagnostics's Tissue of Origin Test presented at ASCO 2011

Pathwork Diagnostics, Inc., a privately held molecular diagnostics company focused on oncology, announced today that results from a decision impact study of its Tissue of Origin Test were presented this weekend at the ASCO 2011 Gastrointestinal Cancers Symposium in San Francisco.

25 Jan 2011

OriGene releases 1,500 mouse monoclonal antibodies

OriGene Technologies, Inc. has recently achieved a significant milestone in its quest for developing an assay for every human protein through the release of 1,500 mouse monoclonal antibodies under the TrueMAB brand. Each TrueMAB antibody is specifically developed with full-length human proteins produced in HEK293T cells and validated for critical research and diagnostic needs requiring improved antibody sensitivity and specificity.

21 Jan 2011

Positive results from nimotuzumab Phase II study for gastric cancer

YM BioSciences, a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development, today announced that results were reported from a randomized Phase II gastric cancer study of nimotuzumab being conducted by its licensees, Daiichi Sankyo Co., Ltd. in Japan and Kuhnil Pharma Co. Ltd., in Korea.

21 Jan 2011

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

MacroGenics, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical trial of MGAH22.

6 Jan 2011

HistoRx grants Metamark worldwide license to AQUA technology for commercialization of Prognostic Assays

Metamark Genetics, Inc., a privately held oncology-focused molecular diagnostics company, and HistoRx, Inc., a diagnostics company developing tissue-based diagnostic solutions to advance individualized patient care, today announced a multi-year licensing agreement. HistoRx has granted Metamark a worldwide license to the AQUA technology for the clinical commercialization of Metamark's proprietary MetamarkDx™ Prognostic Assays.

20 Dec 2010

Genomic Health announces results of Oncotype DX test in early-stage breast cancer patients

"We provide optimal care to breast cancer patients when we treat the underlying biology of their individual tumors," said Steven Shak, MD, chief medical officer of Genomic Health.

14 Dec 2010

Clarient introduces Mammostrat test to quantify likelihood of breast cancer recurrence

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of Mammostrat, a patented, novel test designed to help quantify the likelihood of recurrence of breast cancer following surgery and initial treatment.

9 Dec 2010

IRIS announces product acquisition from BioMicro Systems

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and a provider of high value personalized medicine products and testing services, announced today that it has acquired the assets of a multi-purpose, bench-top instrument platform for automating highly repetitive, manual laboratory protocols for (F)ISH (fluorescence in-situ hybridization) testing and other slide-based cytogenetic applications.

30 Nov 2010

Warfarin taken along with herbal, dietary supplements may be dangerous

Herbal and dietary supplements are popular. People claim they make their joints feel better, their bones stronger, and their hearts healthier. But a recent study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City shows that many of these people may not realize their favorite supplement, mixed with prescription medications, may be putting their lives in danger, especially if they are taking warfarin - a blood-thinning medication commonly prescribed to patients living with atrial fibrillation to lower their risk of stroke.

17 Nov 2010

NeoGenomics third quarter revenue grows 19% to $8.7 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the third quarter 2010.

28 Oct 2010